Allarity Therapeutics ALLR Stock
Allarity Therapeutics Price Chart
Allarity Therapeutics ALLR Financial and Trading Overview
| Allarity Therapeutics stock price | 1.13 USD |
| Previous Close | 0.19 USD |
| Open | 0.19 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 0.18 - 0.2 USD |
| 52 Week Range | 0.17 - 81.9 USD |
| Volume | 731.67K USD |
| Avg. Volume | 3.69M USD |
| Market Cap | 3.85M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 0.00045714423 |
| EPS (TTM) | -15.65 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ALLR Valuation Measures
| Enterprise Value | 9.87M USD |
| Trailing P/E | 0.00045714423 |
| Forward P/E | -0.009641776 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.609 |
Trading Information
Allarity Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -99.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 81.9 USD |
| 52 Week Low | 0.17 USD |
| 50-Day Moving Average | 0.51 USD |
| 200-Day Moving Average | 12.97 USD |
ALLR Share Statistics
| Avg. Volume (3 month) | 3.69M USD |
| Avg. Daily Volume (10-Days) | 2.32M USD |
| Shares Outstanding | 20.14M |
| Float | 19.11M |
| Short Ratio | 0.11 |
| % Held by Insiders | 0.71% |
| % Held by Institutions | 0.066% |
| Shares Short | 280.56K |
| Short % of Float | 1.46% |
| Short % of Shares Outstanding | 1.46% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:35 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.17% |
| Return on Equity (ttm) | -197.52% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -16202000 USD |
| Net Income Avi to Common (ttm) | -19755000 USD |
| Diluted EPS (ttm) | 418.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 352K USD |
| Total Cash Per Share (mrq) | 0.02 USD |
| Total Debt (mrq) | 3.8M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.256 |
| Book Value Per Share (mrq) | -2.61 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14263000 USD |
| Levered Free Cash Flow (ttm) | -13465125 USD |
Profile of Allarity Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 24 School Street |
| ZIP | 02108 |
| Phone | (401) 426-4664 |
| Website | https://allarity.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Q&A For Allarity Therapeutics Stock
What is a current ALLR stock price?
Allarity Therapeutics ALLR stock price today per share is 1.13 USD.
How to purchase Allarity Therapeutics stock?
You can buy ALLR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Allarity Therapeutics?
The stock symbol or ticker of Allarity Therapeutics is ALLR.
Which industry does the Allarity Therapeutics company belong to?
The Allarity Therapeutics industry is Biotechnology.
How many shares does Allarity Therapeutics have in circulation?
The max supply of Allarity Therapeutics shares is 17.01M.
What is Allarity Therapeutics Price to Earnings Ratio (PE Ratio)?
Allarity Therapeutics PE Ratio is now.
What was Allarity Therapeutics earnings per share over the trailing 12 months (TTM)?
Allarity Therapeutics EPS is -15.65 USD over the trailing 12 months.
Which sector does the Allarity Therapeutics company belong to?
The Allarity Therapeutics sector is Healthcare.
Allarity Therapeutics ALLR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}